Background: Ursodeoxycholic acid (UDCA) prolongs transplantation-free survival in primary
biliary cirrhosis (PBC). However, the optimal therapeutic dose has not been established …

The use of model for end‐stage liver disease (MELD) score for liver allocation has resulted
in transplanting sicker patients. As such, it is unclear whether the risk factors and severity of …

Abstract Background/Aims: Endogenous hydrophobic bile acids are suspected to be one of
the pathogenetic factors of biliary complications after orthotopic liver transplantation (OLT) …

A group of 195 consecutive adult patients who received a primary orthotopic liver allograft
were reviewed retrospectively to analyze the incidence of rejection, the response to …

Background. Chronic viral hepatitis averages 15% to 20% in heart transplant patients.
Several studies have shown that ursodiol may improve liver biochemistry in patients with …

Protocol biopsy results in the first few weeks after liver transplantation sometimes display
histologic features of acute cellular rejection (ACR), even in the absence of significant …

Orally given ursodeoxycholic acid (UDCA) has beneficial effects on laboratory parameters in
different cholestatic conditions. In order to investigate the effect on early graft function after …

Results All patients were transplanted within 6 months from insertion on the waiting list.
Longitudinal analysis of the treated group showed that cholestasis and cytolisis parameters …

OBJECTIVE Randomized, double-blind, placebo-controlled trials of ursodeoxycholic acid
(UDCA) in patients with primary biliary cirrhosis (PBC) have not demonstrated improvement …

Several studies suggest that UDCA treatment has beneficial effects in chronic cholestatic
diseases. We designed a controlled trial to assess the efficacy and tolerance of UCDA in …